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Abstract
Adenovirus vector-based vaccine is a promising approach to protect HIV infection. However, a recent phase IIb clinical trial
using the vector did not show its protective efficacy against HIV infection. To improve the vaccine, we explored the
transgene protein expression and its immunogenicity using optimized codon usage, promoters and adaptors. We compared
protein expression and immunogenicity of adenovirus vector vaccines carrying native or codon usage-optimized HIV-1
clade C gag and env genes expression cassettes driven by different promoters (CMV, CMVi, and CA promoters) and adapters
(IRES and F2A). The adenovirus vector vaccine containing optimized gag gene produced higher Gag protein expression and
induced higher immune responses than the vector containing native gag gene in mice. Furthermore, CA promoter
generated higher transgene expression and elicited higher immune responses than other two popularly used promoters
(CMV and CMVi). The second gene expression using F2A adaptor resulted in higher protein expression and immunity than
that of using IRES and direct fusion protein. Taken together, the adenovirus vector containing the expression cassette with
CA promoter, optimized HIV-1 clade C gene and an F2A adaptor produced the best protein expression and elicited the
highest transgene-specific immune responses. This finding would be promising for vaccine design and gene therapy.
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Introduction
The human immunodeficiency virus (HIV), responsible for
acquired immune deficiency syndrome (AIDS), is classified into
type 1 and type 2. HIV type 1 (HIV-1) is further classified into 11
phylogenetically related genetic subtypes (clades) from A to K.
HIV-1 clade B is dominant in developed countries, such as North
America and Western Europe, and has been the primary focus of
vaccine development. A phase IIb clinical trial of an adenovirus
serotype 5 (Ad5) vector-based HIV-1 IIIb vaccine (STEP trial)
failed to protect against HIV infection [1,2]. Further, HIV-1 clade
C is the most dominant subtype (approximately half of HIV
infected people) [3] in the world, especially in developing countries
such as India [4], China [5], and the Sub-Saharan African
countries [6]. Therefore, the development of a vaccine against
HIV-1 clade C is urgently required.
In this study, we investigated the immunogenicity of HIV clade
C genes driven by three promoters and with two adaptor
sequences in a bicistronic Ad vector. We used the replication-
defective Adenovirus type 5 (Ad5) vector containing adenovirus
type 35 fiber (Ad5/35) as a vaccine vector [7]. Ad5/35, in
common with Ad35, uses CD46 as a receptor for infection [8].
CD46 is expressed on the majority of human cells, enabling the
Ad5/35 vector to transduce a wide range of human tissues. The
tropism to the liver and hepatotoxicity of Ad5/35 was much lower
than for Ad5 [9].
The immunogenicity of a vaccine vectoris not onlydependent on
the vector but also on the magnitude of antigen expression. Several
promoters have been widely studied in mammalian cells and
animals, such as virus-origin promoters (CMV, CMVi, CA, Sra,
and LTR promoters) and tissue-origin promoters (EF1a and p53
promoters). The CMV promoter has been widely used for
expression in mammalian cells, since it is much strong compared
to other promotes. To optimize an Ad vector-based HIV clade C
vaccine, we compared the expression and immunogenicity of HIV-
1 clade C genes driven by different promoters (CMV, CMVi, and
CA promoters) and adapters (IRES and F2A), using native and
optimized genes. It has been reported that optimized genes showed
higher protein expression in vitro and the immunogenicity of a DNA
vaccine in vivo was higher when compared to native genes [10,11].
The CMV promoter is derived from the human cytomegalovirus
immediate-early 1 gene promoter, and the CMVi promoter consists
of the CMV promoter and an intron A. The CA promoter consists
of the CMV enhancer and the chicken b-actin promoter with the
chicken b-actin intron. Plasmids with the CMVi promoter or the
CA promoter have higher levels of gene expression than plasmids
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Gag and Env proteins in a bicistronic vector, we used internal
ribosome entry site (IRES) sequences [13,14], furin cleavage site
and2A(F2A)sequences,orfusiontypes ofgagoptand envopt.IRES
sequences derived from the encephalomyocarditis virus (EMCV)
are commonly used in gene therapy and gene transfer experiments
[15], but the expression of the IRES-dependent second gene is
much lower than the expression of the catabolite activator protein
(cap)-dependent first gene [16]. The F2A adaptor is linked to a furin
cleavage site in the foot-and-mouth-disease virus (FMDV) 2A
sequence [17,18]. F2A has been shown to express high levels of a
full-length, functional monoclonal antibody (mAb), in vitro and in
vivo, where F2A was used to link the heavy and light chains of the
mAb [17,18].
In this study, we explored the immunogenicity of adenovirus
vectors with different promoters, adaptors, and genes. The best
transgene expression and immunogenicity were obtained from an
adenovirus vector containing the CA promoter with an F2A
adaptor and an optimized transgene.
Results
In vitro protein expression analysis of the HIV-1 clade C
gag gene
To compare the expression efficiency of the HIV clade C Gag
protein among several gag expression cassettes (Figure 1) in vitro,
HeLa cells were transduced with plasmids (pCMV-gagopt,
pCMVi-gag, pCMVi-gagopt, or pCA-gagopt) or infected with
Ad vectors (Ad-CMV-gagopt, Ad-CMVi-gag, Ad-CMVi-gagopt,
or Ad-CA-gagopt) (Figure 1). After two days of incubation, Gag
protein expression was analyzed by western blotting with an anti-
HIV clade C gag p24 mAb, and the intensity of Gag was
quantified with Image J software. p55
Gag and two or three extra
proteins containing p24 were detected (Figures 2A and 2B). We
considered that these extra proteins were incompletely processed
proteins with cellular proteases and speculate as follows: the
48 kDa band may consist of p17, p24 and p7; the 42 kDa band
may consist of p17 and p24; and the 38 kDa band may consist of
p24, p7 and p6. We calculated the relative protein intensity of total
Gag protein expression to the levels of the native Gag protein. In
the context of the influence of the gag gene sequence, the
optimization of the gene sequence increased its expression to
approximately 170 fold in plasmid-transfected cells (pCMVi-
gagopt vs pCMVi-gag), and 590 fold in Ad-infected cells (Ad-
CMVi-gagopt vs Ad-CMVi-gag) (Figures 2A and 2B). No
remarkable difference of Gag protein expression was observed in
the cells transfected with gagopt-expressing plasmids with different
promoter (CMV, CMVi and CA) (Figure 2A). However, CA
promoter driving vector (Ad-CA-gagpot) expressed two-fold
higher Gag protein than the vectors driven by CMV promoter
(Ad-CMV-gagopt) and CMVi promoter (Ad-CMVi-gagpot).
Significant higher gag mRNA in HeLa cells infected with Ad-
Figure 1. Schematic design of the expression cassettes used in this study. CMV, CMV immediate promoter and enhancer (CMV-IE); CMVi,
CMV-IE with intron A; CA, CMV enhancer and chicken b-actin promoter with b-actin intron; gagopt, optimized HIV96ZM651 gag coding gene; gag,
native HIV96ZM651 gag coding gene; envopt, optimized HIV96ZM651 envelope gp160 coding gene; IRES, internal ribosome entry site sequence from the
encephalomyocarditis virus; F2A, a combination of furin cleavage site and 2A self-processing sequence; pA, polyadenylation signal sequence.
doi:10.1371/journal.pone.0030302.g001
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gagopt and Ad-CMVi-gagopt, p,0.01 and p,0.05, respectively)
(Figure 2C). Taken together, we found that gagopt expression
cassette driven by CA promoter is the best expression efficiency of
the HIV clade C Gag protein in our cassettes indicated in figure 1.
Immunogenicity of the clade C gag expression cassette
in the Ad vectors
To investigate the immunogenicity of the Ad vectors, BALB/c
mice were intramuscularly immunized with Ad-CMV-gagopt, Ad-
CMVi-gag, Ad-CMVi-gagopt, Ad-CA-gagopt, or Ad-CMV-LacZ
(Figure 1). Ten days post-immunization, the frequency of Gag-
specific CD8 T cells in PBMCs (Figure 3A) and splenocytes
(Figure 3B) was measured with H-2D
d/p24 tetramer
(AMQMLKDTI). The tendency of the immune response against
Gag in PBMCs was similar with that in splenocytes. A strong Gag-
specific cell-mediated response was detected in the mice
immunized with gagopt-expressing Ad vector (Ad-CMVi-gagopt),
but not with naı ¨ve gag-expressing Ad vector (Ad-CMVi-gag)
(Figures 3A and 3B), demonstrating that corresponding to the
results of mRNA and protein expression, optimized gene is better
than native viral gene for virus-based vaccine vector.
Then we investigated the immunogenicity of Ad vectors
expressing optimized gag gene driven by various promoters.
Again, The CA promoter driven Ad vector (Ad-CA-gagopt)
induced significantly higher Gag-specific CD8 T cells than the
vector driven by CMVi promoter (Ad-CMVi-gagopt) and CMV
promoter (Ad-CMV-gagopt) (p,0.05) (Figures 3A and 3B),
demonstrating that CA promoter elicits higher protein expression
and immune responses in viral vector than other two promoters.
Recently, it has been reported that polyfunctional CD8 and
CD4 T cell responses, which produce multiple cytokines in a
single-cell, are associated with lower plasma viral loads in patients
with chronic HIV infection [19,20]. Therefore, we evaluated the
HIV-1 clade C Gag-specific cell-mediated immune response by
multicolor intracellular cytokine staining (ICS) and the productiv-
ity of INF-c, TNF-a and CD107a in PBMCs and splenocytes ten
days post-immunization. As shown in Figure 4, gagopt-expressing
Ad vectors produced significantly higher cytokine-producing CD8
T cells (including single, double and triple cytokine-secreting cells)
in both PBMCs (Figure 4A, 4B) and splenocytes (Figure 4C, 4D)
than the naı ¨ve gag-expressing Ad vector (Ad-CMVi-gag). CA
promoter driven Ad vector (Ad-CA-gagopt) produced further
higher polyfuctional cytokine-producing CD8 T cells than other
promoter-driven Ad vectors. These results demonstrate that Ad-
CA-gagopt induces higher polyfunctional HIV-1 clade C Gag-
specific CD8 T cells than that of Ad-CMVi-gag, Ad-CMV-gagopt
or Ad-CMVi-gagopt in BALB/c mice.
To investigate HIV-1 clade C Gag-specific humoral immune
responses, antibody (Ab) against Gag was measured 8 weeks after
immunization by ELISA (Figure 5). As we observed with the cell-
mediated responses, the Ad-CA-gagopt induced significantly
higher gag-specific Ab (p,0.05) than the other vaccines. Similar
level of Ab was induced by Ad-CMV-gagopt and Ad-CMVi-
gagopt. These results indicate that Ad-CA-gagopt induces higher
HIV-1 clade C Gag-specific humoral immune responses than that
of Ad-CMVi-gag, Ad-CMV-gagopt or Ad-CMVi-gagopt in
BALB/c mice.
In conclusion, we found that immunization of Ad-CA-gagopt to
mice induced higher Gag-specific polyfunctional Gag-specific cell-
mediated immunity and humoral immunity than that of Ad-
CMVi-gag, Ad-CMV-gagopt or Ad-CMVi-gagopt.
Protein expression and immunogenicity of the HIV-1
clade C env gene downstream of the gag gene
To investigate the expression efficiency of the second gene, env
was introduced to downstream of gag in a bicistronic vector. We
constructed vectors containing a fusion type protein without any
Figure 2. Analysis of HIV clade C Gag protein expression. HeLa cells were transfected with 2 mg of plasmid (pCMV-gagopt, pCMVi-gag,
pCMVi-gagopt, or pCA-gagopt) (A) or infected with the corresponding Ad vector at MOI 5 (Ad-CMV-gagopt, Ad-CMVi-gag, Ad-CMVi-gagopt, or Ad-
CA-gagopt) (B). Untreated HeLa cells were used as a negative control. After two days of incubation, the cells were harvested, and proteins were
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) electrophoresis, transferred, and assayed by western
immunoblotting using a Gag-specific Ab. To calculate the Gag protein relative intensity, the cell lysates from pCMVi-gag or Ad-CMVi-gag constructs
were 10- or 50-fold more loaded in these lanes than in any of the other lanes, respectively. The number indicates the mean relative protein intensity
to the Gag protein. Data are representative of five independent experiments. (C) Analysis of gagopt mRNA expression in HeLa cells infected with Ad-
CMV-gagopt, Ad-CMVi-gagopt or Ad-CA-gagopt by quantitative real-time PCR. HeLa cells were infected with the corresponding Ad vector at MOI 2
(Ad-CMV-gagopt, Ad-CMVi-gagopt or Ad-CA-gagopt). After two days of incubation, total RNA was isolated from infected cells and cDNA was
generated. cDNA was used as a template for quantitative real-time PCR. Data represent the mean 6 standard error of the mean (S.E.M.) and are
representative of two independent experiments. *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0030302.g002
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IRES-E) or F2A (G-F2A-E). These expression cassettes were
separately introduced to a plasmid or the Ad vector. HeLa cells
were then transduced with these bicistronic vectors. After 2 days of
incubation, Env protein expression was analyzed by western
blotting with an anti-HIV clade C Env Ab (Figure 6). We used b-
actin protein, not Gag protein, as an internal control, because Gag
protein was expressed as a fusion protein with Env by plasmid
pGE or adenovirus vector Ad-GE. On membrane probed with the
anti-Env Ab, the upper band was estimated to be the fusion
protein of Gag and Env, and the lower band as Env protein
including the fusion protein that was generated by cellular
proteases. The intensity of the Env protein was analyzed with
Image J software and the relative intensity from pG-IRES-E
(Figure 6A) or Ad-G-IRES-E (Figure 6B) were shown. In both
cases, the env gene that was linked to the gag gene by the F2A
sequence was expressed most effectively (Figures 6A and 6B). The
Gag protein expression in these bicistronic vectors was equivalence
(data not shown). Taken together, we found that the env
expression efficiency introduced downstream of gag in a
bicistronic vector with F2A is the best expression efficiency of
HIV-1 clade C Env protein in our cassettes indicated figure 1.
To explore the peptide for ICS of HIV clade C env, we i.m.
immunized mice with 10
8 pfu of Ad-G-F2A-E. Ten days after
immunization, mouse splenocytes were isolated and stimulated
with HIV consensus clade C env pool (obtained from AIDS
Research and Reference Reagent Program). The peptide pool
contains 212 peptide with 15-mer amino acid and 10-mer overlap
each other. We separated the peptides to 12 groups (group1-10
contains 20 peptides per group, group 11 contains 12 peptides,
Figure 3. HIV Gag-specific CD8 T cells in mice. Balb/c mice (5–6/group) were immunized with 1610
8 pfu of Ad vector (Ad-CMV-gagopt, Ad-
CMVi-gag, Ad-CMVi-gagopt, Ad-CA-gagopt, or Ad-CMV-LacZ) with intramuscular injection. Ad-CMV-LacZ was used as a negative control vector. Ten
days post-immunization, the frequency of clade C Gag-specific CD8 T cells in PBMCs (A) or splenocytes (B) was measured by the H-2Dd/p24 tetramer
assay in 5-6 individual mice. Data represent the means 6 S.E.M. and are representative of two independent experiments. *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0030302.g003
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secreting CD8 T cells were detected from mouse splenocytes. We
found 0.313%, and 0.116% of env-specific response was observed
in the splenocytes stimulated with group 10 (env region 721-811
amino acid), and all pool (env region 1-856 amino acid),
respectively (data not shown). Other peptide groups induced
0.016%–0.082% IFN-c-secreting CD8 T cells. Then we used
group 10 peptide pool to detect HIV clade C env-specific cell-
mediated responses.
To explore the immunogenicity of the second gene, we
immunized mice with Ad-G-IRES-E, Ad-GE, or Ad-G-F2A-E.
Ten days after immunization, mouse splenocytes were isolated and
stimulated with the group 10 peptide pool. As shown in figures 7A
and 7B, significantly higher IFN-c-single- and IFN-c/TNFa-
double positive CD8 T cells were observed in vaccine groups than
that in control group. Ad-G-F2A-E vector induced higher IFN-c-
single- and IFN-c/TNFa-double cytokine producing CD8 T cells
than other vaccines. Furthermore, Ad-G-F2A-E also induced
significantly higher levels of Env-specific Ab at 4, 6 and 8 weeks
after the immunization as compared to the other vaccines
(Figure 7C, p,0.05 at 4 and 6 weeks, p,0.01 at 8 weeks). In
conclusion, we found that immunization of Ad-G-F2A-E to mice
induced higher env-specific cellular and humoral immunity than
that of Ad-G-IRES-E, Ad-GE.
Discussion
To optimize an HIV clade C vaccine based on the Ad vector,
we compared the immunogenicity of HIV clade C genes driven by
various elements in mice. As expected, gagopt induced stronger
immunity than native gag. Moreover, we compared the immuno-
genicity of gagopt controlled by three different promoters, the
CMV, CMVi, and CA promoters. The Ad vector with the CA
promoter induced the most Gag-specific CD8 T cells, polyfunc-
tional CD8 T cells and Gag-specific Ab. Among the bicistronic
vectors, the F2A-dependant env gene induced more Env-specific
Ab titers.
It has been reported that plasmid-introduced optimized gag
induced higher immunity [10] but Ad-based vaccines with
optimized genes have not been studied. We observed that gagopt
was expressed more efficiently in HeLa cells as compared to native
gag. This was probably because the human optimized gag gene
was translated easier than native gag.
HIV-specific cytotoxic T lymphocytes (CTL) are important for
the suppression of HIV replication, because vaccine-induced virus-
specific CTL responses emerge during HIV acute infection and
reach to the peak at 7 to 14 days [21,22,23,24]. It has been
reported that the HIV core protein, Gag-specific T cell reaction
affects the suppression of HIV replication in HIV or Simian
Figure 4. Polyfunctional analysis of HIV clade C Gag-specific CD8 T cells. The same murine samples shown in Fig. 3 were tested by
multicolor ICS assay for production of INF-c, TNF-a and CD107a. (A) or (C) are shown for each individual combination of functions of HIV clade C Gag-
specific CD8 T cellsin PBMCs or splenocytes, respectively. (B) or (D) are shown for each combination of functions (three, INF-c+TNF-a+CD107a+; two,
INF-c+TNF-a+,INF-c+CD107a+ and TNF-a+ CD107a+; one, INF-c+, TNF-a+and CD107a+) of HIV clade C Gag-specific CD8 T cells in PBMCs or
splenocytes, respectively. These were measured by multicolor ICS assay following stimulation with clade C p24 peptide. IFN-c, TNF-a and CD107a
were used as the functional markers. This assay was performed in 5-6 individual mice. Data represent the means 6 S.E.M. and are representative of
two independent experiments. *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0030302.g004
Optimized Ad5/35 HIV Vaccine
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mice were intramuscularly immunized with an Ad vector
expressing HIV clade C gag, and ten days post-immunization
that are the peak of Gag-specific CTL responses, the immunoge-
nicity was analyzed with the p24 tetramer assay and multicolor
ICS. HIV elite controllers possess HIV-specific polyfunctional
CD8 T cells, and it is important to analyze CD8 T cells
polyfunctionally and not monofunctionally [19,28]. We analyzed
mouse CD8 T cells with antibodies recognizing INF-c, TNF-a or
CD107a [29] as T cell functional markers. Ad-CMVi-gagopt
induced stronger immunity than Ad-CMVi-gag. This result
correlated with the expression efficiency of gag analyzed by
western blot analysis. The comparison between the three types of
promoters used in this study demonstrated that the CA promoter
induced HIV-specific and polyfunctional cell-mediated immunity
more effectively overall but less than for the CMV and CMVi
promoters in TNF-a or CD107a single producers (Fig. 4). It is
possible that the single producers, except for INF-c decreased for
other functional cell groups were increased in Ad-CA-gagopt
immunized mice. On the other hand, such phenomena were not
Figure 5. HIV clade C Gag-specific humoral immune response. Eight weeks post-immunization, HIV clade C Gag-specific Ab titer was
measured by ELISA. Diluted immune sera from 800 to 12,800-fold were used for ELISA. The ELISA plate was coated with HIV clade C p24 protein. The
detection of Gag-specific Ab titer was performed at an absorbance of 450 nm. This assay was performed in 5-6 individual mice. Data represent the
means 6 S.E.M. and are representative of two independent experiments. *, p,0.05.
doi:10.1371/journal.pone.0030302.g005
Figure 6. Analysis of the expression of HIV clade C Env protein from the bicistronic vectors. HeLa cells were transfected with plasmid
(pG-IRES-E, pGE, or pG-F2A-E) (A) or infected with Ad vector (Ad-G-IRES-E, Ad-GE, or Ad-G-F2A-E) at MOI 5 (B) (Fig. 1). Untreated HeLa cells were used
as a negative control. After two days of incubation, the cells were harvested and proteins were separated by SDS-PAGE electrophoresis, transferred
and assayed by western immunoblot using an Env-specific Ab (HIV clade C gp120 mAb). The number indicates the mean relative protein intensity to
the expression of the Env protein containing the IRES cassette. Data are representative of five independent experiments.
doi:10.1371/journal.pone.0030302.g006
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at inducing triple producers and double producers, INF-c and
CD107a. There appears to be an inconsistence between data of
Fig. 3 and Fig. 4. This is thought to be the one by difference of the
character of two assays. Tetramer assay measure antigen-specific
T cell numbers, whereas multicolor ICS assay measure antigen-
specific T cell functions. These assays are not necessarily
equivalent [30,31].
To express two antigens in a bicistronic vector, we used three
different approaches, IRES-, F2A-dependent or a fusion type. The
F2A-dependant second gene showed a greater efficiency of
expression in HeLa cells and higher immunogenicity in mice.
Difficulties regarding the expression efficiency of the second gene
have been reported in the use of IRES elements and fusion type
genes. IRES-dependant expression can be significantly lower than
cap-dependant expression [16]. On the other hand, F2A-
dependant expression was very stable in cell lines and in mice
[32]. We speculate that this difference in expression efficiency of
the second gene depends on the mode of expression. IRES
sequences allow the initiation of translation in a cap-independent
way [15] and F2A sequences work as a self-cleavage site in
peptides [18,33]. To our knowledge, there are no reports about
the comparison of second gene expression dependent on adapter
sequences. Probably, this F2A-dependant cleavage occurs more
efficiently than internal ribosomal binding in mammalian cells. As
Syzmczak et al. pointed out, the small 2A peptide at the end of the
C-terminus of the protein may contribute to the antigenicity of
proteins [32]. The F2A sequences used in this study were 2A
sequences adjacent to a furin cleavage site; most of the Gag protein
had no additional peptide at its C-terminus, and free-2A peptide
should exist in mice [17]. However, in rare cases the Gag protein
can still have a small peptide at its C-terminus. We investigated the
immunogenicity of Gag, the first gene in the bicistronic vector, by
the H-2K
d/p24 tetramer assay. Significant differences in Gag-
specific immunity were not detected between the three types of
linkage (data not shown). There is not sufficient information
regarding the safety of the F2A peptide in the clinical setting.
Further research should be conducted for F2A-dependant
bicistronic vectors with the aim of advancing towards clinical
trials.
Although the efficiency of expression of the fusion protein was
the second best in this study, the immunogenicity of Env induced
by Ad-GE was approximately the same as Ad-G-IRES-E. Ad-GE
expresses the Env protein not only as a single protein but also as a
fusion protein (Fig. 6B). Whether processing of this fusion protein
occurs in the proteasome or whether some TAP-dependent
transaction steps take place in the antigen presentation cells has
not been established. It is likely that the Gag part of the fusion
protein was processed properly since immune responses to Gag
were observed using the tetramer assay (data not shown). The
Figure 7. HIV clade C Env-specific humoral immune response. HIV clade C Env-specific Ab titer was measured by ELISA. The mice (6/group)
were immunized with 1610
8 pfu of Ad vector (Ad-G-IRES-E, Ad-GE, or Ad-G-F2A-E). Eight hundred-fold diluted immune sera were used for ELISA. The
ELISA plate was coated with HIV clade C Env peptide. The detection of Env-specific Ab titer was performed at an absorbance of 450nm. This assay was
performed with 6 individual mice sera. Data represent the means 6 S.E.M. and are representative of two independent experiments. *, p,0.05;
**, p,0.01.
doi:10.1371/journal.pone.0030302.g007
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not clear. Further analysis should be conducted for the use of a
fusion protein as an antigen.
Vaccination with recombinant Ad5 has achieved great success
in inducing protection against virus infection in several animal
models [34] and inducing HIV-specific responses in clinical trial
[35]. Ad5 is well characterized, and its subclinical disease
association in humans is well known [36]. However, a majority
of the human population (more than 60%) is infected with the Ad5
virus [37]. The neutralizing antibody and the cellular immune
responses against the Ad5 fiber and capsid may reduce the efficacy
of the Ad5 vector when it is used in a clinical trial [38]. This study
used a chimera Ad5 vector with Ad35 fiber, which relates with cell
tropism. The Ad5/35, similar to Ad5, has a high productive titer
in tissue culture cells, because it is commonly known that human
subgroup B adenoviruses, such as Ad5, have a considerably higher
titer as compared with other subgroup viruses, including Ad35.
Nevertheless, the virus displayed the cell tropism of Ad35. Using
the Ad5/35 vector, we found that high immunogenicity of the
vaccine was observed in both mice and non-human primates
[39,40]. Coupled with the evidence that an Ad5/35 vector
transduces human dendritic cells more efficiently as compared
with an Ad5 vector [41], these findings suggest that the Ad5/35-
HIV vector is a promising candidate for human trials.
In this study, the expression of the fusion type env protein in
HeLa cells was higher than the IRES-dependant expression. A
similar phenomenon has been reported, and the authors
speculated that the efficiency of the reinitiation of translation of
the second gene [42] could be dependent on the gene and cell
combination. The precise mechanism leading to the higher
efficiency of expression of the second gene in HeLa cells is
unknown [16].
In summary, we have demonstrated that a CA promoter-
controlled optimized HIV-1 clade C gene and an F2A-dependant
second gene induced efficient gene expression and high antigen-
specific immunity. These data should be taken into account for the
use of these elements in the development of an HIV clade C
vaccine and for gene therapy.
Materials and Methods
Cells
HEK293 and HeLa cells were cultured in Dulbecco’s Modified
Eagle’s Medium (Wako Pure Chemical Industries, Ltd., Osaka,
Japan) with 10% fetal calf serum.
Plasmids
The native HIV-1 clade C gag gene (strain 96ZM651.8) was
amplified from recombinant vaccinia virus DNA (vT331 obtained
from AIDS Research and Reference Reagent Program, National
Institutes of Health, Rockville, MD; Cat. No. 6523). The codon
optimized HIV-1 clade C gag gene (gagopt) and envelope gp160
gene (envopt) were amplified from p96ZM651gagopt and
p96ZM651gp160opt (obtained from the AIDS Research and
Reference Reagent Program; Cat. No. 8675 and No. 8662),
respectively. Three promoters were used to drive the expression
of the antigen: the cytomegalovirus immediate-early 1 gene
(CMV) promoter, the CMV promoter with the largest intron of
CMV (intron A) sequence (CMVi), and the CMV enhancer and
the chicken b-actin promoter with the chicken b-actin intron
sequence (CA) (Fig. 1). Native gag (gag) or optimized gag (gagopt)
were subcloned into the shuttle plasmid pHMCMV10 [12] under
the control of the CMVi promoter to generate pCMVi-gag and
pCMVi-gagpot, respectively. Optimized gag (gagopt) was sub-
cloned in shuttle vector pHMCMV6 [43] or pHMCA5 [44] to
generate pCMV-gagopt or pCA-gagopt, respectively. The shuttle
vectors contain promoter-transgene-poly A cassette between the
restriction enzyme sits, I-CeuI and PI-SceI.
To construct double gene expression plasmid, gagopt and
envopt were cloned into the plasmid pIRES (Clontech, Mountain
View, CA, USA) containing an IRES sequence. The gagopt-
IRES-envopt fragment was then subcloned into the multiple
cloning site of pHMCA5 [44], under the control of the CA
promoter to generate pG-IRES-E. The gagopt, F2A and envopt
genes were fused and subcloned into pHMCA5 to generate pG-
F2A-E. The F2A oligonucleotides coding for the F2A peptide were
synthesized based on the sequence RAKRAPVKQTLNFDLLK-
LAGDVESNPGP [32]. The fusion gene of gagopt and envopt was
subcloned in pHMCA5 to generate pGE.
Ad virus
I-CeuI/PI-SceI fragment of the shuttle plasmid containing the
gene expression cassette was ligated into pAdHM34 [7],
containing the E1/E3-deleted adenovirus type 5 genome with
type 35 fiber. The resulting plasmid was digested with PacI and
transfected into HEK293 cells with SuperFect Transfection
Regent (Qiagen GmbH, Hilden, Germany) according to the
manufacturer’s instructions to generate the Ad virus. These Ad
vectors were propagated in HEK293 cells and purified by CsCl2
gradient centrifugation; dialyzed with a solution containing
10 mM Tris (pH 7.5), 1 mM MgCl2, and 10% glycerol; and
stored in aliquots at –80uC. Determination of the virus particle
and infectious titers (plaque forming unit, PFU) was accomplished
spectrophotometrically by the methods of Maizel et al. [45] and
Kanegae et al. [46], respectively.
Western blot
HeLa cells were transfected with plasmids using Lipofectamine
2000 Regent (Invitrogen, Carisbad, CA, USA) or infected with Ad
vectors at a multiplicity of infection (MOI) of 5. After two days of
incubation, the cell lysates were suspended with a low salt
extraction buffer (10 mM Tris-HCl, 0.14 M NaCl, 1 mM
dithiothreitol, 2 mM phenylmethanesulfonyl fluoride, 0.5% Non-
idet P-40, and 3 mM MgCl2) for 30 min on ice. The lysates were
mixed with an equal volume of 2 6sodium dodecyl sulfate (SDS)
buffer (125 mM Tris-HCl, pH 6.8; 4% SDS; 20% glycerol; 0.01%
bromophenol blue; and 10% beta-mercaptoethanol) and boiled for
10 min. The cell lysates were then loaded onto an 8%
polyacrylamide gel. Proteins were transferred to a Hybond ECL
nitrocellulose membrane (Amersham Pharmacia Biotech, Buck-
inghamshire, England). For primary antibodies, we used an HIV-1
clade C p24 mAb (lab prepared monoclonal antibody, unpub-
lished) and an HIV-1 clade C gp120 mAb (laboratory-prepared
monoclonal antibody, unpublished) to detect the Gag protein and
the gp160 protein, respectively. Anti-b-Actin mAb (AC-15, Sigma,
Saint Louis, MO, USA) was used as an internal control. A
horseradish peroxidase (HRP)-conjugated anti-mouse IgG Ab
(Cappel Laboratories Inc., PA, USA) was used as the secondary
Ab. The blots were developed by using the ECL Plus western
blotting detection system (Amersham Pharmacia Biotech).
Quantitative Real-time PCR
HeLa cells were infected with Ad vectors at MOI of 2. After two
days of incubation, total RNA was isolated from infected cells
using ISOGEN (Nipongene, Toyama, Japan) and cDNA was
generated using SuperScript
TM II Reverse Transcriptase (Invitro-
gen, Carisbad, CA, USA). cDNA was used as a template for real-
time PCR in triplicates with SYBR Premix Ex TaqTM II
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Forward: 59-atcgaggaggagcagaacaa-39, Reverse: 59-gttctgcac-
gatggggtagt-39, human Gapdh; Forward: 59-ggtggtctcctctgactt-
caaca-39, Reverse: 59-gtggtcgttgagggcaatg-39). PCR and analysis
were performed on an Applied Biosystems StepOne Plus Real-
time PCR system (Applied Biosystems, Foster City, CA, USA).
The expression of each gene was normalized with human Gapdh.
Ad-mediated mouse immunization
Eight-week-old female BALB/c mice (H-2Dd) were purchased
from Japan SLC Inc., Hamamatsu, Japan. The mice were
intramuscularly administered with 1610
8 pfu of the Ad vector.
The Ad vector carrying the CMV-LacZ-pA expression cassette
was used as a negative control vector.
Tetramer assay
The assay was performed as previously described [39,47] A
phycoerythrin (PE)-conjugated H-2K
d/p24 tetramer (AMQM
LKDTI) was prepared by the National Institute of Allergy and
Infectious Disease MHC Tetramer Core Facility (Yerkes Regional
Primate Research Center, Atlanta, GA, USA). In brief, 10 days
post-immunization,peripheralbloodmononuclearcells(PBMCs)or
splenocytes were obtained from the immunized mice and stained
with the tetramer and a fluorescein isothiocyanate (FITC)-
conjugated anti-mouse CD8a Ab (Ly-2; eBioscience, San Diego,
CA, USA) for 30 min at room temperature. The red blood cells
wereremoved andthe leucocyteswerefixedwith OptiLyseBLysing
Solution (Beckman Coulter, Fullerton, CA, USA) according to the
manufacturer’s instructions. Then the PBMCs or splenocytes were
washed twice with the staining buffer (3% fetal calf serum (FCS),
0.09% NaN3 in phosphate-buffered saline (PBS)) and analyzed on a
flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) using
CellQuest software (Becton Dickinson).
Multicolor intracellular cytokine staining (ICS) assay
HIV-1 clade C Gag-specific, polyfunctional CD8
+ T cells were
detected 10 days after immunization with the Cytofix/CytoPerm
Plus kit according to the manufacturer’s instructions (Pharmingen,
San Diego, CA, USA). In brief, PBMCs were obtained from
immunized mice, and the red blood cells were removed by using a
Lysing Buffer (BD Bioscience Pharmingen, Franklin Lakes, NJ,
USA). Lymphocytes were incubated with 10 mg/ml of HIV-1
clade C p24 peptide (AMQMLKDTI) and a FITC-conjugated
anti-mouse CD107a Ab (1D4B; Southern Biotechnology Associ-
ates Inc., Birmingham, AL, USA) for the detection of Gag-specific
responses in a 24-well plate for 1 h at 37uC, followed by an
additional 5 h in the presence of 1 mg/ml of BD GolgiStop (BD
Bioscience Pharmingen). The cells were washed with staining
buffer and stained with allophycocyanin (APC)-Cy7-conjugated
anti-mouse CD8a Ab (53-6.7; BioLegend, San Diego, CA, USA)
at 4uC for 30 min. The cells were suspended in 250 ml of Cytofix/
Cytoperm solution at 4uC for 15 min, washed with Perm/Wash
solution (BD Bioscience Pharmingen), and stained with PE-
conjugated anti-mouse IFN-c Ab (XMG1.2, eBioscience) and
APC-conjugated anti-mouse TNF-a Ab (MP6-XT22, eBioscience)
for 30 min at 4uC. The cells were acquired by Moflo cytometer
(Beckman Coulter, Fullerton, CA, USA). Data were analyzed
using FlowJo (Treestar).
To detect env-specific cellular immunity responses, we used a
15-mer amino acid peptide pool with 11-mer overlap of HIV
consensus subtype C env (obtained from AIDS Research and
Reference Reagent Program; Cat. No. 9499). The peptide pool
contains 20 peptides ranged from No. 721-811 amino acid of HIV
clade C env (peptide Cat. No. 9365-9384). Splenocytes were used
for detection of env-specific cytokine secretion using ICS assay as
detection of gag-specific immunity responses (2 mg/ml per peptide
was used for stimulation).
Enzyme-linked immunosorbent assay
The HIV-1 clade C p24 protein [48] or envelope V3 peptide
(NNTRQSIRIGPGQTFYATGDIIGD) were used for the detec-
tion of HIV-1 clade C Gag-specific Ab or HIV-1 clade C gp160
Ab, respectively.Briefly, 96-well microtiter plates were coated with
10 mg/ml of HIV clade C p24 peptide or V3 peptide and
incubated overnight at 4uC. The wells were blocked with PBS
containing 1% BSA for 2 h at 37uC. They were then treated with
100 ml of diluted sera and incubated for an additional 2 h at 37uC.
The bound immunoglobulin was quantified using an HRP-
conjugated anti-mouse IgG Ab (diluted 1:1,000; Cappel, Labora-
tories Inc., PA, USA). The mean Ab titer was measured at a
wavelength of 450 nm by using a microplate reader (Model 450;
Bio-Rad, Hercules, CA, USA).
Data analysis
All results were expressed as the mean 6 standard error of the
mean. Statistical analysis of the experimental and control data was
performed using a one-way factorical analysis of variance. P-
value,0.05 defined statistically significant.
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